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To establish a persistent latent infection, Epstein-Barr virus (EBV) faces a challenge in that the virus-infected host cell must transit
through the germinal centre reaction. This is a site of B cell diﬀerentiation where antibody responses are optimised, and the
selection criteria for B cells are stringent. The germinal centre environment is harsh, and the vast majority of B cells here die
by apoptosis. Only cells receiving adequate survival signals will diﬀerentiate fully to be released into the periphery as long-term
memory B cells (the site of persistence). In this review, we detail the apoptotic pathways potentially encountered by EBV-infected
B cells during the process of infection, and we describe the functions of those EBV-regulated cellular and viral genes that help
promote survival of the host B cell.
1. Introduction
1.1. The Challenge Faced by EBV to Establish a Latent Infec-
tion. Epstein-Barr virus (EBV) persistently infects greater
than 90% of the population, and, in the vast majority of
cases, the infection remains benign for life. To establish a
persistent latent infection, EBV must access the memory B
cell compartment and reside within long-lived peripheral B
cells [1] where few viral gene products are expressed in order
to escape immune detection. One current model suggests
that, to establish latency, EBV transmitted in infected saliva
first infects IgD+ve naı¨ve B cells within the tonsils of the
nasopharyngeal lymphoid system. EBV-infected cells are
then thought to express a limited set of viral genes called the
latency III or growth program [2] (see Figure 1). More recent
evidence, however, has suggested that transient expression of
some lytic cycle genes are also required for the early stages of
infection but without eliciting virion production (reviewed
in [3]). Following infection, an initial phase of naı¨ve B cell
activation and proliferation is driven by viral genes which
is orchestrated by the viral transcription factor EBNA-2 [4].
EBNA-2 regulates the transcription of all other latent genes as
well as a host of cellular genes including the proto-oncogene
c-MYC [5, 6]. Inadequate cytotoxic T-cell responses at this
stage of infection can lead to infectious mononucleosis (IM)
which is characterised by expansion of EBNA-2-positive
B cells—a pathological condition not evident in normal
carriers. In IM, the normal zonal architecture of the germinal
centre (GC) is disrupted due to the extensive proliferation of
virally infected cells. In this disease state, there is evidence
that EBV may infect and drive the proliferation of cells other
than naı¨ve cells (including memory and/or (GC) cells) in
order to rapidly spread throughout the B cell population
[7]. The extraordinary proliferative capacity of EBV-infected
B cells expressing the growth program is evident during
in vitro culture since infection of resting or GC B cells
results in rapid establishment of continuously proliferating
immortalised lymphoblastoid cell lines (LCLs) [8]. Through
the expression of the latency III genes, EBV infection may
also alter the usual phenotypic characteristics of diﬀerent B
cell subsets [9]. However, studies where normal tonsil tissue
sections have been dissected and analysed for EBV status
and B cell phenotype suggest that, in vivo, the expansion
of latency III type lymphoblasts is restricted. Instead, the
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EBV-infected cells enter GCs and actively participate in
B cell diﬀerentiation. During this time, EBV gene expression
gradually becomes more limited due to the downregulation
of EBNA-2 (reviewed in [10]). EBV-infected cells expressing
only the latency II program (EBNA-1, LMP-1, and LMP-
2) have been detected within GCs, and these infected
cells retain phenotypic markers of GC centroblasts and
centrocytes [11, 12]. These studies suggest that latently
infected cells have arisen following diﬀerentiation of newly
infected blasts which transit normally through the GC
reaction before finally emerging into the peripheral memory
B cell pool carrying latent episomal viral DNA. Here the virus
resides selectively (although not exclusively) within isotyped-
switched members of the CD27+ve, IgD−ve memory B
cell population [13, 14]. At this stage, the cells are in
what is termed the latency 0 stage, expressing only EBV-
encoded RNA (EBERs) (Figure 1). It is possible that EBV
could access memory B cells via diﬀerent routes, possibly
depending on whether the infection gives rise to the majority
of asymptomatic infections or infectious mononucleosis.
However, since EBV-infected cells can transit through GCs,
it follows that the cells must somehow survive during B
cell diﬀerentiation in order to establish latency. The GC is
a hostile environment for B cells. The greater proportion
of them undergoes apoptosis induced as a result of the
elimination of all but those B cells expressing the highest
aﬃnity immunoglobulins. In the next sections, we discuss
the apoptotic signalling pathways that regulate GCB cells and
finally consider the virally encoded gene products that may
influence host cell survival and thus establishment of viral
latency.
1.2. The GC Microenvironment
1.2.1. The GC Reaction. High levels of apoptosis are induced
in GCs in order to select eﬀector plasma cells or memory
cells capable of expressing high-aﬃnity immunoglobulins of
specific subtypes. The process begins with the recognition of
antigen by the B cell receptor, along with cognate priming
of T-helper cells by antigen presenting dendritic cells. It is
generally thought that these activated B cells entering the GC
first proliferate rapidly within the “dark zone” (histologically
defined as a densely populated area of Ki67+ve/CD77+ve
centroblasts). Cells accumulate somatic hypermutations in
their immunoglobulin genes which has the advantage of
potentially increasing the specificity of the BCR for its
antigen (aﬃnity maturation), but, also necessitates the
elimination of B cells with autoreactive and low-aﬃnity
receptors [15]. The centroblasts diﬀerentiate further into
nonproliferating centrocytes and migrate to the GC “light
zone” which contains follicular dendritic cells (FDCs) and
T cells. Centrocytes carrying the highest aﬃnity, mutated
receptors outcompete others for the limiting amounts of
foreign antigen displayed on follicular dendritic cells and
for the survival signals provided by helper T cells [16]. In
the absence of these survival signals, GC B cells undergo
rapid apoptosis. Although the general architecture of the
GC is described here, proliferation and apoptosis are not
necessarily confined to the dark and light zones, respectively,
as cells may traﬃc between the two regions (reviewed in
[17]). In addition, within the light zone, a proportion of
centrocytes undergo class switching by DNA recombination
to express either IgG, IgA, or IgE and alter the function
of their immunoglobulins. In summary, several individ-
ual signalling pathways activated during the GC reaction
(described inmore detail below) form an interconnected web
of proapoptotic cues which only the most stringent set of
survival criteria can overcome.
1.2.2. Proapoptotic Signals during T-Cell-Dependent B Cell
Responses. Apoptotic pathways, responsible for the elimi-
nation of B cells within the GC signal through the TGF-β
receptor, B cell receptors, and FAS (outlined schematically
in Figure 2). Using the Burkitt lymphoma model of GC
apoptosis, and comparing cells isolated from tonsil tissue,
we have shown previously that autocrine TGF-β signalling
via the type 1 TGF-β receptor ALK5 contributes to the
default apoptotic state of normal GC B cells when they fail
to secure survival cues from their microenvironment (death
by neglect) [18]. TGF-β causes cell death independently
of the death receptors FAS and TRAIL [19], by inducing
the intrinsic apoptosis pathway. Intrinsic apoptosis requires
the activation of two members of the BCL-2 family of
apoptosis regulators, BAX, and BAK. These proteins reside in
mitochondrial membranes and are responsible for regulating
membrane permeability, the release of apoptotic factors into
the cytoplasm, and ultimately the activation of an initiator
of the caspase cascade (caspase 9). As well as regulating GC
B cell homeostasis in the normal GC microenvironment,
TGF-β signalling is also required for IgA class switching
and secretion [20–22]. Proapoptotic signals are also received
following the activation of the B cell antigen receptor
(BCR) in the absence of T-cell help. This negative selection
process is induced as a result of weak or inappropriate
BCR ligation and is critical for eliminating B cells carrying
autoreactive or low-aﬃnity B cell receptors which can
arise due to somatic hypermutation and class switching of
immunoglobulin genes. In this context, signalling through
the B cell receptor, like TGF-β, induces intrinsic apoptosis.
An alternative “extrinsic,” FAS-dependent apoptosis pathway
also causes spontaneous apoptosis in cells lacking suﬃcient
T-cell help during diﬀerentiation.
Coincidentally ligation of the TGF-β and BCR receptors
results in the induction of the viral lytic cycle by activating
the latent-lytic switch gene BZLF-1 [23, 24]. The BZLF-1
promoter contains multiple Smad-binding elements which
act in concert to induce gene transcription [25]. Once
established, the lytic programme in its own right protects
B cells from apoptosis through late gene expression [26],
but the function of BZLF-1 is context dependent. Productive
viral infection only occurs after BZLF-1 expression when the
viral DNA is methylated (i.e., after latent infection is already
established) [27].
At what point EBV blocks an apoptotic signalling
pathway, whether at the receptor level or downstream at the
level of the eﬀector proteins inducing apoptosis, may be
determined by the various stages of virus cycle and/or
diﬀerentiation state of the host cell. The mechanisms of
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Figure 1: Model of establishment of EBV latency in B cells. EBV infects naı¨ve IgD-positive B cells and drives their proliferation by expression
of the viral latency III genes, including the latent membrane proteins LMP1, LMP2A, and LMP2B, the EBV nuclear antigens EBNA1, 2, LP,
3A, 3B, and 3C and noncoding RNA species, the EBV-encoded RNAs (EBERS), and BamHI-A rightward transcripts (BARTs). In vitro, these
blasts form continuously proliferating immortalised, lymphoblastoid cell lines (LCLs). EBV-infected cells participate in the GC reaction
during which time the number of viral gene products expressed decreases due to the downregulation of the viral transcription factor EBNA-
2. Following diﬀerentiation, long-lived memory B cells emerge as the site of persistent latent infection carrying viral episomal DNA and
expressing few viral genes to avoid immune surveillance. ∗Transient lytic gene expression may occur but without virion production.
apoptosis induction and the variousmeans employed by EBV
to abrogate apoptosis are discussed below.
1.3. Mechanisms of Apoptosis Induction
1.3.1. TGF-β Signalling Pathway in B Cell Apoptosis. TGF-
β signals by enabling the formation of a heterotetrameric
complex of the high-aﬃnity type II receptor (TβRII) and
the type I receptor, ALK5. TβRII is a constitutively active
serine threonine kinase which, upon receptor complex
formation, phosphorylates and activates ALK5, inducing a
signalling cascade via the canonical Smad pathway and/or
several non-Smad pathways [28, 29]. TGF-β stimulation
of ALK5 results in c-terminal phosphorylation of the
receptor-regulated Smads, Smad2 (ser465/476) and Smad3
(ser433/435). Following phosphorylation, Smads 2 and 3
bind to the co-Smad, Smad4, and the resulting heteroli-
goomeric complexes accumulate within the nucleus to both
positively and negatively regulate target gene expression
[30]. Phosphorylated (activated) Smad2 has been detected
by immunohistochemistry within sections of dark and light
zones of GC reactions [18]. In centroblasts isolated from
GCs, several of the apoptotic genes regulated by TGF-β
signalling have been characterised and include members of
the BCL-2 family acting upstream of BAX and BAK in the
intrinsic apoptosis pathway.
The BCL-2 family members which tightly regulate the
function of BAX and BAK include the prosurvival factors
BCL-2, and its homologues, BCL-XL, MCL-1, BFL-1, BOO,
and BCL-w. Other members of the family, sharing one
region of homology with BCL-2 (BH3-only proteins) (BIK,
BID, NOXA, BIM, BAD, HRK, PUMA, and BMF), are
proapoptotic. Direct “activators” of BAX and BAK [31]
include BIM, tBID (the active, truncated form of BID),
and PUMA [31–33] which activate BAX/BAK by direct
binding in response to apoptotic stimuli. The prosurvival
factors like BCL-2 prevent apoptosis by sequestering these
“activator” proteins, but they themselves may be inhibited
by interaction with specific BH3-only proteins [34]. These
proteins are often referred to as apoptosis “sensitisers” which
may either free activators from the prosurvival factors to
enable BAX/BAK activation [35] or, alternatively, block the
direct interaction of prosurvival factors with BAX and BAK
[36]. The mechanism of action of TGF-β in centroblasts
and Burkitt’s lymphoma lines involves the induction of an
apoptotic program via transcriptional upregulation of the
proapoptotic BH3-only proteins PUMA (our unpublished
observations) and BIK, while also downregulating the pro-
survival factor BCL-XL. The increase in BH3-only proteins
and the loss of BCL-XL expression lead to mitochondrial
membrane depolarisation and intrinsic apoptosis [18].
1.3.2. Mechanisms of BCR and FAS-Induced Apoptosis. Like
TGF-β, signalling via the BCR causes an increase in BH3-
only protein expression and induces the intrinsic apoptosis
pathway. The proapoptotic proteins BIK and BIM are both
induced by BCR signalling. BIM is able to bind all BCL-
2 prosurvival proteins making it a highly potent inducer of
apoptosis and a critical factor in the homeostatic control of
B cells. Its regulation by the BCR is complex involving both
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Figure 2: EBV infection impacts on cell death and survival pathways in GC B cells. Interconnected signalling pathways regulate the apoptosis
of GC B cells. Proapoptotic signals via B cell receptors and the canonical Smad pathway activated by the TGF-β receptor control the
elimination of unwanted B cells by inducing intrinsic apoptosis. Intrinsic apoptosis is dependent on the activation of the proapoptotic BCL-2
family members BAX and BAK, permeabilisation of the mitochondrial membrane (ΔΨm) and release of proapoptotic factors resulting in the
activation of the initiator caspase, caspase 9. An extrinsic apoptotic pathway occurs via the death receptor FAS. FAS stimulation results in the
formation of the death-inducing signalling complex (DISC) comprised of FAS, the Fas-associated death domain (FADD), and pro-caspase 8.
GC B cells, however, have a preformed DISC whose activation is inhibited by binding of the protein cFLIP. The cells are, therefore, dependent
on continuous survival signals via CD40 for maintenance of cFLIP levels. CD40 signalling (along with other signals through BLyS (BAFF)
and the BCR not shown on this diagram) also induces BCL-2 family members such as BFL-1 and BCL-XL which promote cell survival by
inhibiting the intrinsic apoptosis pathway. EBV gene products target multiple points in the apoptosis pathways (shown in red). ∗In vitro
studies of cell lines report the LMP-1-dependent upregulation of BCL-2, however, LMP-1 and BCL-2 expression levels do not correlate in
primary tissue.
transcriptional and posttranslational mechanisms (reviewed
in [37]). FAS, on the other hand, activates the “extrinsic”
apoptosis pathway independent of the BCL-2 family and
the mitochondrial response. Unusually, GC B cells have a
preformed FAS death-inducing signalling complex (DISC)
which lacks any requirement for ligand binding for its
activation. Instead, the preformed DISC is held in an inactive
form complexed with cFLIPL. In the absence of adequate
GC survival signals from cell-cell contact with T cells and
follicular dendritic cells, cFLIP is degraded, the initiator
pro-caspase 8 within the complex is activated, and the cells
undergo rapid spontaneous apoptosis [38, 39]. Targeting
mitochondrial apoptosis during EBV infection would have
the advantage of potentially inhibiting both TGF-β and BCR-
induced death, whereas FAS-induced apoptosis (which is
independent of the BCL-2 family and mitochondria) would
need to be targeted selectively.
1.4. Prevention of BCR, FAS, and TGF-β-Induced Apoptosis
by EBV. The viral latent membrane protein LMP-1, which
is induced by EBNA-2 and expressed during the growth
programme, mimics constitutively active CD40. LMP-1
regulates NF-κB activity (amongst other signalling pathways)
and, in essence, provides the survival signals usually associ-
ated with T-cell help. CD40 signalling via NF-κB in GC B
cells induces the expression of cFLIP and renders the cells
FAS resistant [40]. LMP-1, therefore, provides precisely the
signals necessary to counteract FAS-induced apoptosis.
A second mimic of functional B cell receptors, LMP-
2A, is expressed by EBV potentially to inhibit negative
selection. EBV LMP-2A functions like its own B cell receptor
by constitutively associating with Syk and the Src family
of tyrosine kinases [41] normally downstream of BCR
signalling. Expressed as part of the growth program, LMP-
2A is often detected in tumour biopsies of EBV-related
malignancies. The eﬀect of encoding its own BCR mimic
is that EBV-infected host cells that have lost the capacity to
receive normal BCR-derived survival signals (as a result of
deleterious or nonsense mutations in the immunoglobulin
genes during GC diﬀerentiation) can be rescued from
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apoptosis [42, 43]. In vitro infection of CD77-positive
(centroblast) GC B cells with EBV can give rise to LCLs with
no surface immunoglobulin [44], while LMP2A expression
in B cells of BCR-negative mice is suﬃcient to maintain
GC formation in lymphoid tissues of the gut [45]. BCR-
negative GC B cells are, therefore, still capable of survival
and proliferation by virtue of their positive EBV status.While
it is apparent that BCR-negative B cells can survive in vitro
and in mouse model systems, there is currently no evidence
to suggest that outgrowth of BCR-negative virally infected
cells actually occurs in humans in the context of a primary
infection with the whole virus. Analysis of immunoglobulin
genes expressed within cells of the peripheral memory B
cell compartment of IM patients failed to detect any cells
expressing defective BCR [14]. In addition, LMP-2A is
downregulated during the latency 0 phase in the memory B
cell compartment and could, therefore, have no further role
in promoting their survival. It seems likely then that LMP-2A
would have a role in augmenting survival in cells with weak
BCR signalling within the GC [46] and potentially during
tumourigenesis of cells carrying other genetic abnormalities.
LMP-2A can also block normal BCR signalling in LCLs that
retain BCR expression [47]; however, in nontransformed
mouse models of BCR activation, B cell survival appears
more dependent on LMP-2A-induced activation of the NF-
κB transcription factor and NF-κB target gene expression
than on preventing BCR signalling [48].
EBV-infected cells transiting through GCs within tonsils
would undoubtedly encounter TGF-β signalling via ALK5.
Once immortalised, EBV-infected LCLs are refractory to the
inhibitory eﬀects of TGF-β signalling. This may, at least
in part, be mediated by LMP-1. Treatment of LCLs with
antisense to LMP-1 modestly sensitises LCLs to the growth
inhibitory eﬀects of TGF-β [49] although other studies found
no evidence that LMP-1 was either necessary or suﬃcient
to block TGF-β responses [50]. In epithelial cells, LMP-1-
induced activation of NF-κB interferes with TGF-β-induced
activation of Smad-responsive reporter constructs [51] while
in epithelial carcinoma cells and Hodgkin lymphoma cell
lines EBNA-1, the viral gene responsible for maintenance
and replication of viral episomal DNA,modulates TGF-β sig-
nalling by reducing Smad2 levels through enhanced protein
turnover [52, 53]. Since the TGF-β apoptosis programme
is multifactorial, it seems unlikely that one viral protein
could be suﬃcient to disrupt the entire apoptotic response.
There are, in fact, numerous points of intersection between
apoptosis eﬀectors and EBV-induced survival signals as well
as substantial cross-talk between the intrinsic apoptosis
pathways of TGF-β and the BCR. The viral genes that
potentially play a role in blocking both TGF-β and BCR-
induced apoptosis will therefore be discussed together in the
next section.
1.5. Viral Products Disrupting the Expression and Function
of Proapoptotic Factors. In some lymphomas associated with
EBV infection (Burkitt’s lymphoma), insensitivity to TGF-β
can result from a loss of type II receptor expression [50, 54]
which correlates with expression of the latency III program
although loss of signalling is not mandatory for antagonising
the antiproliferative eﬀects of TGF-β [55]. This implies that
there must be further checks and balances on TGF-β target
gene expression and/or function to abrogate its eﬀects.
In EBV-infected epithelial cells, the viral latent mem-
brane protein LMP-1 is involved in blocking TGF-β-
mediated antiproliferative eﬀects. LMP-1 can prevent TGF-
β-induced cell cycle arrest by suppressing the TGF-β-induced
expression of the transcription factor ATF3. Lack of ATF3
induction enables TGF-β-mediated expression of Id1 (which
would otherwise be inhibited by ATF-3) [56] and the
presence of Id1 inhibits TGF-β-induced cytostasis [57]. In
B cells, TGF-β-induced cytostasis can occur if the apoptotic
response is blocked. However, ATF3 does not appear to be
a TGF-β target gene in B cells, even in the absence of EBV
infection. Id1 protein is upregulated by TGF-β, but, in B cells,
growth arrest can proceed uninterrupted in the presence of
Id1 [58]. It, therefore, seems unlikely that LMP-1 regulation
of Id1 expression may have a role in interfering with TGF-
β-mediated growth arrest in B cells although this has not
been tested during infection of resting B cells. Further studies
are needed using primary infected material to determine
whether LMP-1 expression in the early phase of infection
overrides the TGF-β cytostatic response in B cells.
1.5.1. Blocking BAX/BAK Function. To potentially combat
cell death induced by TGF-β, EBV employs a variety of
prosurvival mechanisms. These include the production of
factors which directly counteract the function or induction
of the proapoptotic BH3-only proteins (see Figure 2). Several
proteins have been implicated in directly blocking the
activation of BAX and BAK whose homooligomerization in
the mitochondrial membrane [59] is required for apoptosis.
In vitro (at least when overexpressed) LMP-1 inhibits BAX
promoter activity through the induction of NF-κB activity
[60]. EBV also expresses two viral BCL-2 homologues.
The two vBcl-2 genes, BHRF-1 and BALF-1, are maximally
expressed just after infection of primary B cells but are not
required once latent infection is established in immortalised
cell lines. Both genes however, are essential in prevention of
spontaneous apoptosis during the earliest stages of infection
[61]. Subsequent structural studies have demonstrated that
BHRF-1 binds to BAK as well as a subset of BH3-only pro-
teins including the TGF-β target gene PUMA, as well as BID
and BIM. Interestingly, recombinant BHRF-1 was unable
to associate with the “sensitiser” BH3-only proteins BAD,
BIK, BMF, HRK, or NOXA [62]. BHRF-1, therefore, appears
to selectively target all three direct BAX/BAK “activators”
which should prove an eﬀective strategy to prevent BAX/BAK
activation.
1.5.2. EBV-Mediated Induction of Cellular Prosurvival BCL-2
Family Members. Manipulation of cellular gene expression,
such as the prosurvival BCL-2 family members BCL-XL,
BCL-2, MCL-1 and BFL-1, may also contribute to the
inhibition of BAX/BAK activation. GC B cells are usually
devoid of BCL-2 expression which is transiently down-
regulated in GC B cells during the transition from naı¨ve to
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memory B cell, while BCL-XL is induced by CD40 or BCR
ligation. Elevated levels of BCL-2 family members in the
GC caused by EBV would be expected to provide a survival
advantage to infected cells. BFL-1 has been reported to be
induced by overexpression of EBNA-2 or LMP-1, through
diﬀerent response elements within the BFL-1 promoter.
EBNA-2-dependent transcriptional regulation occurs via
a CBF-1/RBP-Jk-binding site [63] while LMP-1-induced
expression is dependent on NF-κB activation [64]. LMP-1 is
also reported to induce both BCL-2 and MCL-1 expression
[65, 66], however, more recent studies in vivo using human
tissue have found no correlation between LMP-1 expression
and expression of BCL-2 [12]. The discrepancy here could be
due to the diﬀerence between in vitro overexpression studies
compared with the function of LMP-1 in vivo in the context
of proportionate, and the correct temporal expression of
LMP-1.
In vivo experiments using transgenic (LMP2A/HEL-Tg)
mice in which B cells express LMP-2A and a specific B cell
receptor recognising hen egg lysozyme have now provided
useful information regarding the potential role of LMP-2A
during BCR activation of EBV-infected cells. There is still the
potential caveat that LMP-2A is overexpressed and functions
in isolation from potential crosstalk with other EBV latent
proteins; nevertheless, this analysis has revealed that LMP-2A
mimics BCR survival signals by inducing BCL-2 expression.
BCL-2 levels were selectively increased in resting, mature B
cells via activation of NK-κB [48]. In another mouse model,
LMP-2A has also been shown to induce BCL-XL through
constitutive activation of the RAS/PI3K/AKT pathway [67].
The activation of PI3K and elevated BCL-XL expression
induced by LMP-2A promoted the survival of BCR-negative
primary B cells in the periphery (pre-B cell survival signals);
however, BCL-XL was not increased by LMP-2A in BCR-
positive mature B cells in LMP2A/HEL-Tg mice. There are,
therefore, potential diﬀerences in the eﬀects of EBV genes
depending on the diﬀerentiation status of the host cell.
Further in vivo studies will help determine which members
of the BCL-2 family provide essential prosurvival functions
and at what stage of EBV infection in vivo.
1.5.3. Blocking BH3-Only Protein Expression and Function.
Acting at a level above in the hierarchy of BCL-2 family
proteins controlling apoptosis, EBV exerts considerable
control over the function or expression of the BH3-only
proteins. BIK and PUMA are both direct target genes of TGF-
β signalling in B cells. PUMA mRNA is also rapidly and
significantly upregulated during spontaneous apoptosis of
centroblasts following their isolation and in vitro culture (our
unpublished observations). PUMA, like BIM, interacts with
all prosurvival factors while BIK selectively inhibits BCL-XL,
BFL-1, or BCL-w [34]. The EBV v-BCL2 homologue BHRF-
1 directly binds to PUMA (which could potentially interfere
with its interaction with other proteins). In addition, EBV
encodes its own microRNA (miR-BART5) [68] and induces
the cellular microRNA miR-155 [69] which both target
PUMA transcripts (discussed below). Over-expression of
BHRF-1 has been reported to block apoptosis induced by
transient transfection of BIK [70], but it does not appear
that the inhibition of BIK function is due to any direct
interaction between BIK and BHRF-1 [62]. Instead, the
eﬀects of BHRF-1 on BIK function are more than likely due
to the inactivation of BAK which, unlike BAX, is required
for BIK-mediated apoptosis [71]. Interestingly, BIK also
mediates host cell suicide in response to protein synthesis
shutoﬀ [71], a process commonly observed following viral
infection, and induced by the EBV early lytic gene BGLF5
[72]. BIK is also required for IFN-γ-induced cell death in
human airway epithelial cells [73]. It is possible, therefore,
that blocking BIK function may have an important role in
evasion of host immune responses.
As well as inhibiting PUMA and BIK function, EBV
infection results in a loss of BIM expression [74, 75]. EBV
activation of ERK1/2 kinase, leading to the phosphorylation
of BIM and its subsequent degradation by the proteosome,
has been proposed as the mechanism for the posttrans-
lational regulation of BIM protein levels [74]; however,
other studies suggest that BIM transcription is inhibited
through expression of two powerful viral transcriptional
repressors EBNA-3A and EBNA-3C [75]. Both viral proteins
are essential for immortalisation of primary B cells. EBNA-
3A and EBNA-3C can cooperate with activated HRas in cell
transformation assays and negatively regulate the activity of
the viral protein EBNA-2 by competing for binding of the cel-
lular DNA-binding protein RBP-Jk/CBF-1 which is needed
to tether EBNA-2 to DNA. In biopsies of EBV-positive
Burkitt’s lymphomas, the BIM promoter is methylated at
CpG dinucleotides suggesting that epigenetic repression of
BIM could have an important role in tumourigenesis [76].
There is support for this hypothesis from studies in Eμ-Myc
transgenic mice which carry a deregulated Myc transgene
under the control of the Ig enhancer region. Deregulation
of Myc resembles the chromosomal translocation event
associated with the development of Burkitt’s lymphoma. In
this model, Bim induction, along with the activation of
the ARF/p53 pathway, is important for mediating apoptosis
caused by the over-expression of Myc. The induction of
Puma following Myc-induced p53 activation also performs
an important tumour suppressor function in this model
which can be overcome, potentially through the induction
of Puma binding BCL-2 prosurvival factors downstream
of LMP-2A (described above and reviewed in [77]). The
loss of a single allele of Bim accelerates the development
of the lymphomas demonstrating that Bim also acts as a
tumour suppressor in B cells undergoing oncogenic stress
[78]. The case for EBNA-3A and EBNA-3C having the
potential to promote EBV-associated malignancy in the face
of deregulated MYC expression is clear. It has not yet been
demonstrated that this function of the EBNA-3s is required
for viral transformation of primary cells, but, given that one
of themajor cellular targets of EBNA-2 is c-MYC as described
earlier, it is entirely plausible that EBNA-3A and EBNA-
3C-mediated repression of BIM is essential during the early
stages of infection to prevent MYC-induced apoptosis. In
addition, both EBNA-3A and 3C are implicated in the joint
repression of p16INK4a [79] and p14ARF [80] required for LCL
proliferation. Down-regulation of BIM following late gene
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expression may also be required during the viral lytic cycle
[81].
1.6. EBV and miRNAs. EBV both regulates the expression of
cellular microRNAs as well as encoding 25 of its’ own pre-
miRNA’s located within noncoding regions of the BHRF-
1 and BART genes. These ultimately generate four mature
BHRF-1 and 40 mature BART miRNAs. microRNAs are
small, single stranded noncoding RNAs which block the
translation of complementary target mRNA transcripts or,
alternatively, result in mRNA degradation. Both of these
functions are mediated by an RNA-induced silencing com-
plex [82]. In-depth analysis of the function of EBV-encoded
miRNA using recombinant mutant viruses unable to process
the longer pre-miRNAs transcripts revealed that, unlike
other herpesviruses such as herpes simplex, cytomegalovirus,
and Kaposi’s sarcoma viruses (which encode microRNAs
to help maintain latency), EBV-produced miRNAs have
no role in lytic cycle regulation or in maintaining latent
infection. Their role primarily seems to involve protecting
newly infected primary B cells from spontaneous apoptosis
and promoting proliferation during the early phase of
infection. Levels of miR-BHRF1-1 and miR-BHRF1-2-3p are
four and two-fold higher, respectively, 5 days after-infection
compared with expression in established LCLs. Although still
expressed in LCL’s, they are of lower abundance and appear
largely redundant in this context [83]. The cellular targets
of the BART miRNAs whose regulation confers a survival
advantage on the newly infected cell are diﬃcult to predict
and are as yet unidentified.
A number of BART miRNA target transcripts, however,
are known and include LMP-1 and the cellular proapoptotic
gene PUMA. The majority of studies on BART miRNAs
have been carried out in nasopharyngeal carcinoma where
BART expression levels are high, so few functional studies
have yet been carried out in a B cell background. Targeting
LMP-1 with a virally encoded microRNA suggests that
the expression levels of LMP-1 are critical and highlights
the importance of interpreting over-expression studies with
care.
1.7. EBV and p53. Resting primary B cells lack p53 expres-
sion and are insensitive to drug-induced DNA damage. Upon
infection with EBV, however, p53 levels increase in line
with the levels found in B cells stimulated by mitogen. The
resultant LCLs are highly sensitive to the activation of p53
by genotoxic agents and undergo apoptosis rather than a
cell cycle arrest [84]. Thus, EBV infection per se does not
block the upstream signals regulating p53 induction and
has no eﬀect on the phosphorylation of p53 in response
to DNA cross-linking agents. Latent EBV infection does,
however, selectively block the ability of p53 to induce p21
in response to DNA-damaging agents inducing cross-links
and distortions (e.g., cisplatin) rather than double-strand
breaks (e.g., etoposide and γ-irradiation). The outcome
of inducing DNA adducts is, therefore, apoptosis rather
than p21-mediated cytostasis [85]. There is evidence that
EBNA-3C can act as a deubiquitinase which leads to
stabilisation of the p53-negative regulator MDM2. The levels
of p53 in EBNA-3C over-expressing cells are consequently
reduced through p53 degradation [86], although in LCLs,
this eﬀect may be diminished by binding of EBNA-LP
(EBNA-5) to MDM2 which reportedly blocks its ability to
target p53 for degradation [87]. The formation of EBNA-
LP/MDM2/p53 complexes has been proposed to block p53-
mediated transcription (of p21) and provide an explanation
as to how rapidly proliferating LCLs tolerate high levels
of wild-type p53 without succumbing to p53-induced cell
cycle arrest [87]. During the lytic cycle, BZLF-1 mediates
p53 degradation independently of MDM2 function thereby
blocking the potential for p53-mediated gene transcription
during productive viral infection [88].
2. Conclusions
Establishment of a persistent latent EBV infection requires
that the infected host cell transits through the GC where
networks of proapoptotic signalling pathways execute a
rigorous selection procedure over the diﬀerentiating B cells.
Few B cells survive this process to diﬀerentiate fully. To
ensure that the EBV-infected host cell is one of them, EBV has
at its disposal an array of prosurvival mechanisms which can
potentially override external stimuli promoting cell death
(such as TGF-β and activation-induced apoptosis) as well as
protecting the cell from oncogenic stresses induced during
EBV-driven cell proliferation. By blocking cell death path-
ways, many of the EBV-encoded proteins also inadvertently
support the accumulation of genetic mutation and thereby
promote tumourigenesis. Sustained expression of the latency
III programme as in post-transplant lymphoproliferative
disease or the more restricted viral gene expression patterns
in Burkitt’s lymphoma (EBNA-1 and occasionally LMP-2A)
and Hodgkin lymphoma (LMP-1, LMP-2, and EBNA-1) are
also likely to make tumours diﬀerentially dependent on the
presence of EBV [89]. It is important to understand when
and where EBV proteins might act to prevent apoptosis and
in what particular circumstances, (e.g., LMP-2A behaves dif-
ferently in diﬀerent situations, inducing expression of BCL-
XL in cells over-expressing Myc [90], but not in normally
infected cells). Due to the scarcity of suitable animal models
of EBV infection, many of the studies carried out to date have
necessarily used established virally infected cell lines or cells
over-expressing single viral genes. The results of functional
analysis of viral proteins using these systems may at times
conflict with the apparent situation in vivo. More detailed
analysis of newer animal models and primary human tissue
may help resolve some of these discrepancies and aid in
the identification of new therapeutic targets in EBV-related
diseases.
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